Not surprised one bit by today's action. Truth the stock might bump little from the trial completion next year though. But, until they get this to market...aka FDA approval the stock is going to languish. What really punished(other than rejection obviously) it is not being able to get re-listed last year.
News 
Market Data 
Discover 
